An investigation for investors in NASDAQ:ADMA shares was announced concerning possible breaches of fiduciary duties by certain directors at ADMA Biologics.
Investors who purchased shares of ADMA Biologics Inc (NASDAQ:ADMA) and currently hold any of those NASDAQ:ADMA shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain ADMA Biologics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Ramsey, NJ based ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. ADMA Biologics Inc reported that its annual Total Revenue rose from $53.07 million in 2013 to $7.18 million in 2015 and that its Net Loss increased from $15.53 million in 2013 to $17.97 million in 2015.
On August 19, 2016, NASDAQ:ADMA shares closed at $5.61 per share.
Those who purchased NASDAQ:ADMA shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego